Blood:骨髓生态位中非造血细胞成分与HSCs的相互作用

2019-08-01 MedSci MedSci原创

阻碍体内造血干细胞(HSCs)调节的一个主要限制是未完全掌握调控HSC命运所依赖的微环境的细胞及分子支。因此,小鼠造血干细胞无法进行较长时间的培养,更不能通过培养而源源不断地生成、维持及扩增。

中心点:

鉴定HSC-生态位相互作用的新型分子调节剂

通过数据库来确定细胞群之间的分子相互作用

摘要:

阻碍体内造血干细胞(HSCs)调节的一个主要限制是未完全掌握调控HSC命运所依赖的微环境的细胞及分子支。因此,小鼠造血干细胞无法进行较长时间的培养,更不能通过培养而源源不断地生成、维持及扩增。

为了克服这一困难,大大提高对骨髓生态位环境及其与造血干细胞之间的分子相互作用的认识至关重要。

研究人员前瞻性地分离了所有主要的非造血细胞生态位成分,并将它们与谱系标记或追踪所定义的生态位细胞进行详细地相互关联。研究人员还编写了一个包含大量可溶性和膜结合配体受体相互作用的数据库,开发了一种基于筛选纯化的生态位细胞和造血干/祖细胞亚群的转录组数据来推算潜在的细胞间相互作用的计算方法。

借此研究人员概述了已明确的生态位成分和HSCs之间的分子关联。总而言之,本研究表明,细胞因子拮抗剂在调节造血干细胞功能中发挥重要作用。

原始出处:

Nicole Mende, et al. Prospective isolation of non-hematopoietic cells of the niche and their differential molecular interactions with HSCs. Blood 2019 :blood.2019000176; doi: https://doi.org/10.1182/blood.2019000176

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1643073, encodeId=c93216430e39f, content=<a href='/topic/show?id=9c079143ce' target=_blank style='color:#2F92EE;'>#HSCs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9143, encryptionId=9c079143ce, topicName=HSCs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc2923099846, createdName=wjcjjian, createdTime=Fri Sep 06 16:30:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798360, encodeId=cf691e98360e2, content=<a href='/topic/show?id=569469028c4' target=_blank style='color:#2F92EE;'>#生态位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69028, encryptionId=569469028c4, topicName=生态位)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Apr 06 01:30:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658606, encodeId=da2c1658606e3, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9140, encryptionId=4d06914052, topicName=HSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bd24890262, createdName=sjq035, createdTime=Thu May 21 02:30:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909284, encodeId=dfc3190928401, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Aug 05 02:30:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681860, encodeId=3c56168186016, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Thu Apr 02 07:30:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471637, encodeId=9c6914e163773, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494685, encodeId=c8ba1494685d1, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621132, encodeId=cc6816211323b, content=<a href='/topic/show?id=6ba69501350' target=_blank style='color:#2F92EE;'>#造血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95013, encryptionId=6ba69501350, topicName=造血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e720195877, createdName=lq1774, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370628, encodeId=3dc43e0628f3, content=新研究不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Thu Aug 01 23:57:17 CST 2019, time=2019-08-01, status=1, ipAttribution=)]
    2019-09-06 wjcjjian
  2. [GetPortalCommentsPageByObjectIdResponse(id=1643073, encodeId=c93216430e39f, content=<a href='/topic/show?id=9c079143ce' target=_blank style='color:#2F92EE;'>#HSCs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9143, encryptionId=9c079143ce, topicName=HSCs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc2923099846, createdName=wjcjjian, createdTime=Fri Sep 06 16:30:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798360, encodeId=cf691e98360e2, content=<a href='/topic/show?id=569469028c4' target=_blank style='color:#2F92EE;'>#生态位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69028, encryptionId=569469028c4, topicName=生态位)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Apr 06 01:30:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658606, encodeId=da2c1658606e3, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9140, encryptionId=4d06914052, topicName=HSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bd24890262, createdName=sjq035, createdTime=Thu May 21 02:30:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909284, encodeId=dfc3190928401, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Aug 05 02:30:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681860, encodeId=3c56168186016, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Thu Apr 02 07:30:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471637, encodeId=9c6914e163773, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494685, encodeId=c8ba1494685d1, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621132, encodeId=cc6816211323b, content=<a href='/topic/show?id=6ba69501350' target=_blank style='color:#2F92EE;'>#造血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95013, encryptionId=6ba69501350, topicName=造血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e720195877, createdName=lq1774, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370628, encodeId=3dc43e0628f3, content=新研究不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Thu Aug 01 23:57:17 CST 2019, time=2019-08-01, status=1, ipAttribution=)]
    2020-04-06 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1643073, encodeId=c93216430e39f, content=<a href='/topic/show?id=9c079143ce' target=_blank style='color:#2F92EE;'>#HSCs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9143, encryptionId=9c079143ce, topicName=HSCs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc2923099846, createdName=wjcjjian, createdTime=Fri Sep 06 16:30:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798360, encodeId=cf691e98360e2, content=<a href='/topic/show?id=569469028c4' target=_blank style='color:#2F92EE;'>#生态位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69028, encryptionId=569469028c4, topicName=生态位)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Apr 06 01:30:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658606, encodeId=da2c1658606e3, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9140, encryptionId=4d06914052, topicName=HSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bd24890262, createdName=sjq035, createdTime=Thu May 21 02:30:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909284, encodeId=dfc3190928401, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Aug 05 02:30:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681860, encodeId=3c56168186016, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Thu Apr 02 07:30:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471637, encodeId=9c6914e163773, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494685, encodeId=c8ba1494685d1, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621132, encodeId=cc6816211323b, content=<a href='/topic/show?id=6ba69501350' target=_blank style='color:#2F92EE;'>#造血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95013, encryptionId=6ba69501350, topicName=造血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e720195877, createdName=lq1774, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370628, encodeId=3dc43e0628f3, content=新研究不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Thu Aug 01 23:57:17 CST 2019, time=2019-08-01, status=1, ipAttribution=)]
    2020-05-21 sjq035
  4. [GetPortalCommentsPageByObjectIdResponse(id=1643073, encodeId=c93216430e39f, content=<a href='/topic/show?id=9c079143ce' target=_blank style='color:#2F92EE;'>#HSCs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9143, encryptionId=9c079143ce, topicName=HSCs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc2923099846, createdName=wjcjjian, createdTime=Fri Sep 06 16:30:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798360, encodeId=cf691e98360e2, content=<a href='/topic/show?id=569469028c4' target=_blank style='color:#2F92EE;'>#生态位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69028, encryptionId=569469028c4, topicName=生态位)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Apr 06 01:30:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658606, encodeId=da2c1658606e3, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9140, encryptionId=4d06914052, topicName=HSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bd24890262, createdName=sjq035, createdTime=Thu May 21 02:30:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909284, encodeId=dfc3190928401, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Aug 05 02:30:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681860, encodeId=3c56168186016, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Thu Apr 02 07:30:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471637, encodeId=9c6914e163773, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494685, encodeId=c8ba1494685d1, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621132, encodeId=cc6816211323b, content=<a href='/topic/show?id=6ba69501350' target=_blank style='color:#2F92EE;'>#造血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95013, encryptionId=6ba69501350, topicName=造血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e720195877, createdName=lq1774, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370628, encodeId=3dc43e0628f3, content=新研究不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Thu Aug 01 23:57:17 CST 2019, time=2019-08-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1643073, encodeId=c93216430e39f, content=<a href='/topic/show?id=9c079143ce' target=_blank style='color:#2F92EE;'>#HSCs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9143, encryptionId=9c079143ce, topicName=HSCs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc2923099846, createdName=wjcjjian, createdTime=Fri Sep 06 16:30:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798360, encodeId=cf691e98360e2, content=<a href='/topic/show?id=569469028c4' target=_blank style='color:#2F92EE;'>#生态位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69028, encryptionId=569469028c4, topicName=生态位)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Apr 06 01:30:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658606, encodeId=da2c1658606e3, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9140, encryptionId=4d06914052, topicName=HSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bd24890262, createdName=sjq035, createdTime=Thu May 21 02:30:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909284, encodeId=dfc3190928401, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Aug 05 02:30:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681860, encodeId=3c56168186016, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Thu Apr 02 07:30:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471637, encodeId=9c6914e163773, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494685, encodeId=c8ba1494685d1, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621132, encodeId=cc6816211323b, content=<a href='/topic/show?id=6ba69501350' target=_blank style='color:#2F92EE;'>#造血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95013, encryptionId=6ba69501350, topicName=造血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e720195877, createdName=lq1774, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370628, encodeId=3dc43e0628f3, content=新研究不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Thu Aug 01 23:57:17 CST 2019, time=2019-08-01, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1643073, encodeId=c93216430e39f, content=<a href='/topic/show?id=9c079143ce' target=_blank style='color:#2F92EE;'>#HSCs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9143, encryptionId=9c079143ce, topicName=HSCs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc2923099846, createdName=wjcjjian, createdTime=Fri Sep 06 16:30:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798360, encodeId=cf691e98360e2, content=<a href='/topic/show?id=569469028c4' target=_blank style='color:#2F92EE;'>#生态位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69028, encryptionId=569469028c4, topicName=生态位)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Apr 06 01:30:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658606, encodeId=da2c1658606e3, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9140, encryptionId=4d06914052, topicName=HSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bd24890262, createdName=sjq035, createdTime=Thu May 21 02:30:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909284, encodeId=dfc3190928401, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Aug 05 02:30:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681860, encodeId=3c56168186016, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Thu Apr 02 07:30:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471637, encodeId=9c6914e163773, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494685, encodeId=c8ba1494685d1, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621132, encodeId=cc6816211323b, content=<a href='/topic/show?id=6ba69501350' target=_blank style='color:#2F92EE;'>#造血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95013, encryptionId=6ba69501350, topicName=造血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e720195877, createdName=lq1774, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370628, encodeId=3dc43e0628f3, content=新研究不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Thu Aug 01 23:57:17 CST 2019, time=2019-08-01, status=1, ipAttribution=)]
    2019-08-03 ylz8405
  7. [GetPortalCommentsPageByObjectIdResponse(id=1643073, encodeId=c93216430e39f, content=<a href='/topic/show?id=9c079143ce' target=_blank style='color:#2F92EE;'>#HSCs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9143, encryptionId=9c079143ce, topicName=HSCs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc2923099846, createdName=wjcjjian, createdTime=Fri Sep 06 16:30:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798360, encodeId=cf691e98360e2, content=<a href='/topic/show?id=569469028c4' target=_blank style='color:#2F92EE;'>#生态位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69028, encryptionId=569469028c4, topicName=生态位)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Apr 06 01:30:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658606, encodeId=da2c1658606e3, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9140, encryptionId=4d06914052, topicName=HSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bd24890262, createdName=sjq035, createdTime=Thu May 21 02:30:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909284, encodeId=dfc3190928401, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Aug 05 02:30:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681860, encodeId=3c56168186016, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Thu Apr 02 07:30:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471637, encodeId=9c6914e163773, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494685, encodeId=c8ba1494685d1, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621132, encodeId=cc6816211323b, content=<a href='/topic/show?id=6ba69501350' target=_blank style='color:#2F92EE;'>#造血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95013, encryptionId=6ba69501350, topicName=造血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e720195877, createdName=lq1774, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370628, encodeId=3dc43e0628f3, content=新研究不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Thu Aug 01 23:57:17 CST 2019, time=2019-08-01, status=1, ipAttribution=)]
    2019-08-03 俅侠
  8. [GetPortalCommentsPageByObjectIdResponse(id=1643073, encodeId=c93216430e39f, content=<a href='/topic/show?id=9c079143ce' target=_blank style='color:#2F92EE;'>#HSCs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9143, encryptionId=9c079143ce, topicName=HSCs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc2923099846, createdName=wjcjjian, createdTime=Fri Sep 06 16:30:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798360, encodeId=cf691e98360e2, content=<a href='/topic/show?id=569469028c4' target=_blank style='color:#2F92EE;'>#生态位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69028, encryptionId=569469028c4, topicName=生态位)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Apr 06 01:30:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658606, encodeId=da2c1658606e3, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9140, encryptionId=4d06914052, topicName=HSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bd24890262, createdName=sjq035, createdTime=Thu May 21 02:30:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909284, encodeId=dfc3190928401, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Aug 05 02:30:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681860, encodeId=3c56168186016, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Thu Apr 02 07:30:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471637, encodeId=9c6914e163773, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494685, encodeId=c8ba1494685d1, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621132, encodeId=cc6816211323b, content=<a href='/topic/show?id=6ba69501350' target=_blank style='color:#2F92EE;'>#造血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95013, encryptionId=6ba69501350, topicName=造血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e720195877, createdName=lq1774, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370628, encodeId=3dc43e0628f3, content=新研究不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Thu Aug 01 23:57:17 CST 2019, time=2019-08-01, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1643073, encodeId=c93216430e39f, content=<a href='/topic/show?id=9c079143ce' target=_blank style='color:#2F92EE;'>#HSCs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9143, encryptionId=9c079143ce, topicName=HSCs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc2923099846, createdName=wjcjjian, createdTime=Fri Sep 06 16:30:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798360, encodeId=cf691e98360e2, content=<a href='/topic/show?id=569469028c4' target=_blank style='color:#2F92EE;'>#生态位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69028, encryptionId=569469028c4, topicName=生态位)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Apr 06 01:30:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658606, encodeId=da2c1658606e3, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9140, encryptionId=4d06914052, topicName=HSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bd24890262, createdName=sjq035, createdTime=Thu May 21 02:30:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909284, encodeId=dfc3190928401, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Aug 05 02:30:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681860, encodeId=3c56168186016, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Thu Apr 02 07:30:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471637, encodeId=9c6914e163773, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494685, encodeId=c8ba1494685d1, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621132, encodeId=cc6816211323b, content=<a href='/topic/show?id=6ba69501350' target=_blank style='color:#2F92EE;'>#造血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95013, encryptionId=6ba69501350, topicName=造血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e720195877, createdName=lq1774, createdTime=Sat Aug 03 14:30:00 CST 2019, time=2019-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370628, encodeId=3dc43e0628f3, content=新研究不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Thu Aug 01 23:57:17 CST 2019, time=2019-08-01, status=1, ipAttribution=)]
    2019-08-01 yydlt

    新研究不错

    0

相关资讯

Am J Pathol:抗生素的副作用:影响青春期后的骨骼发育

众所周知,肠道菌群对我人体健康至关重要,大多数时候,我们都能与它们和谐共处。肠道微生物组调节我们的一系列生物功能,其中包括骨骼健康。

SCLC二线治疗三大药物造福小细胞肺癌患者

今年ASCO大会上报道了SCLC二线治疗的三大药物,给SCLC的治疗带来了春天,我们一睹为快。

ARCH PATHOL LAB MED:一项结合病理驱动的算法测试和骨髓检查的综合报告

美国病理学家学会发表指南,建议对血液肿瘤进行骨髓综合分析报告。评估结合骨髓检查综合报告的病理驱动算法测试(PDAT)对测试利用率、提供特定的世界卫生组织诊断的能力以及实施一年后临床医生满意度的影响。 本研究回顾了12个月内的血液病报告、综合报告和辅助检测结果。将血液学报告的初步诊断结果与综合报告的最终诊断结果进行比较。测试使用数据与前一年进行对比,由临床医生自行决定在前一年辅助测试。匿名调查

PNAS:骨髓细胞分泌蛋白组具有心脏保护性

由于许多基质细胞类型(包括骨髓衍生的基质细胞(BMSC))显示组织特异性反应,因此需要在组织和损伤类型的背景下探索它们的分泌动力学。

RARS型骨髓增生异常综合征患者伴有ph染色体阳性1例

患者男性,68岁。2014年12月因乏力、气短就诊于当地医院,诊断为“贫血”未治疗。2015年4月上述症状加重就诊于中国医科大学附属第四医院,入院体格检查中度贫血貌,结膜苍白,全身皮肤黏膜无出血点及黄染,浅表淋巴结无肿大,胸骨无压痛,双肺呼吸音清,心律齐,未闻及病理杂音,肝脾肋下未触及,四肢无水肿。实验室检查显示:白细胞7.9×109/L,红细胞2.37×1012/L,血红蛋白75 g/L,外周血